Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY

Background EMPA–KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan. Methods Eligibility required an estimated glomerular filtration rate (eGFR) of ≥ 20

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental nephrology 2024-06, Vol.28 (6), p.588-595
Hauptverfasser:	Nangaku, Masaomi, Herrington, William G., Goto, Shinya, Maruyama, Shoichi, Kashihara, Naoki, Ueki, Kohjiro, Wada, Jun, Watada, Hirotaka, Nakashima, Eitaro, Lee, Ryonfa, Massey, Dan, Mayne, Kaitlin J., Tomita, Aiko, Haynes, Richard, Hauske, Sibylle J., Kadowaki, Takashi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Albuminuria - drug therapy Antidiabetics Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Cardiovascular Diseases Creatinine Death Diabetes mellitus Disease Progression Double-Blind Method End-stage renal disease Epidermal growth factor receptors Female Glomerular filtration rate Glomerular Filtration Rate - drug effects Glucosides - adverse effects Glucosides - therapeutic use Humans Japan - epidemiology Kidney - drug effects Kidney - physiopathology Kidney diseases Kidney Failure, Chronic - drug therapy Male Medicine Medicine & Public Health Middle Aged Nephrology Placebos Rapid Communication Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - physiopathology Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Treatment Outcome Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background EMPA–KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan. Methods Eligibility required an estimated glomerular filtration rate (eGFR) of ≥ 20
ISSN:	1342-1751 1437-7799 1437-7799
DOI:	10.1007/s10157-024-02489-4